1558 — Yichang Hec Changjiang Pharmaceutical Co Balance Sheet
0.000.00%
Last trade - 00:00HealthcareSpeculativeMid Cap
- HK$13.97bn
- HK$14.88bn
- CNY3.72bn
Annual balance sheet for Yichang Hec Changjiang Pharmaceutical Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 2,045 | 1,131 | 1,214 | 1,693 | 1,408 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 600 | 547 | 1,037 | 2,113 | 2,257 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 3,264 | 2,057 | 5,014 | 6,053 | 5,033 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 3,026 | 3,281 | 3,705 | 3,850 | 4,608 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 9,561 | 10,542 | 11,890 | 12,744 | 12,429 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 4,161 | 1,238 | 4,941 | 4,332 | 2,841 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 4,670 | 4,733 | 6,005 | 4,809 | 3,921 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Total Equity | 4,891 | 5,808 | 5,885 | 7,936 | 8,508 |
| Total Liabilities & Shareholders' Equity | 9,561 | 10,542 | 11,890 | 12,744 | 12,429 |
| Total Common Shares Outstanding |